The Scientific Advisory Board is comprised of nationally prominent medical scientists eminent biomedical experts who monitor the progress of scientific matters funded by the institute and advise the Taubman Institute director about matters of strategy and policy.
Dr. George Poste
Dr. Poste is Chief Scientist, Complex Adaptive Systems Initiative (CASI), Regents’ Professor and Del E. Webb Chair in Health Innovation at Arizona State University. He assumed this post in February 2009. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine.
Dr. Poste founded the Biodesign Institute at ASU and served as Director for 2003 to 2009. In creating this Institute, He designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $300 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering.
He serves on the Board of Directors of Monsanto (since 2003), Exelixis (since 2004), Caris Life Sciences (since 2005), and the Scientific Advisory Board of Synthetic Genomics (since 2009). From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as ‘R&D Scientist of the Year’ by R&D Magazine, in 2006 he received the Einstein award from the Global Business Leadership Council and in 2009 received the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry.
He has published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by HM Queen Elizabeth II as a Commander of the British Empire for his contributions to international healthcare and security.
He is a Fellow of the Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He served as a member of the Defense Science Board from 2003 to 2009 and Health Board of the US Department of Defense (DoD) and is currently a member of the US Institute of Medicine Board on Global Health. He has served as a member of Advisory Committees for multiple U.S. Government Agencies in areas of defense, national security and healthcare.
Douglas Greene, MD
Dr. Greene is Founder and Chief Consultant, DAGPHAMED LLC, Partner and Chief Clinical Advisor to Business Stimulus Consultants LLC, and Chief Medical Officer of Neuronasal LLC. Dr. Greene served as Executive Vice President, Chief Scientific Officer and Head, Research and Development, Ikaria Pharmaceuticals from May 2010 until July 2015. From April 2009 to April 2010, Dr Greene served as Senior Vice President and Senior Scientific Advisor at Sanofi-Aventis, a global pharmaceutical company.
From August 2006 to March 2009, Dr Greene served as Senior Vice President and Chief Medical Officer of the US business at Sanofi-Aventis. From June 2003 to July 2006, Dr Greene served as Head of Corporate Regulatory Development at Sanofi-Aventis. Dr Greene was Executive Vice President of Clinical Sciences and Product Development at Merck Research Laboratories and Corporate Officer of Merck, Inc. from May 2000 to January 2003. Dr Greene served as Chairman of the External Board of Scientific Advisors to Merck, Inc from 1994 to 2000.
Dr Greene was a member of the US Food and Drug Administration’s Endocrinologic and Metabolic Drug Advisory Committee from 1988 to 1994, and acted as Chairman of the Advisory Committee from 1990 to 1994. From 1986 to 2000, Dr. Greene was Professor of Internal Medicine, Director of the Michigan Diabetes Research and Training Center, and Chief, Division of Endocrinology & Metabolism at the University of Michigan School of Medicine.
Dr. Greene was Associate Professor of Internal Medicine, Director of the Diabetes Research Laboratory and Head of the General Clinical Research Center at the University of Pittsburgh from 1980-1986, and Assistant Professor of Internal Medicine at the University of Pennsylvania from 1975-80. Dr. Greene completed a post-doctoral research fellowship at the Cox Research Institute at the University of Pennsylvania from 1972-5, and Internal Medicine internship and residency at Johns Hopkins Hospital from 1970-2. Dr Greene holds an MD from the Johns Hopkins School of Medicine and an AB in Biology from Princeton University.
Hamilton Moses III, MD
Dr. Moses is a neurologist (movement disorders), management consultant, author, and conservationist. He is the founder and chairman of Alerion Advisors, LLC, and its associated Alerion Institute.
Dr. Moses has advised corporations, hospitals, foundations, and governments as a partner and senior advisor with the Boston Consulting Group, where he led the science and technology practice in North America, Europe, and Asia; was the chief physician and COO of The Johns Hopkins Hospital; and was chief of psychiatry of the Partners Health System (Massachusetts General, Brigham, and McLean Hospitals) in Boston; and professor of business (strategy) at the University of Virginia’s Darden School of Business.
Over the last two decades he has served as a founder, non-executive director, or member of the scientific advisory boards of a variety of established and new companies in fields as diverse as educational television, CNS drug discovery, genetics, diagnostics, protective products, and information technology.
He is the author of 200 scholarly publications in neuropharmacology, strategy, corporate governance, research investment, and science policy. At Johns Hopkins he co-edited Osler’s Principles and Practice of Medicine and co-founded The Johns Hopkins Medical Letter – Health After 50, a popular letter for the public. Dr. Moses currently serves as chairman of the Land Trust of Virginia. and has received several conservation awards.
David Parkinson, MD
Dr. Parkinson has served as President and Chief Executive Officer of ESSA Pharma Inc. since January 2016, and as a director of the company since June 2015. Prior to joining ESSA he had been a Venture Partner at New Enterprise Associates, Inc.
From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, Inc., a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy. Until October 2007 he was Senior Vice President, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as VP, Oncology Development, at Amgen and VP, Global Clinical Oncology Development, at Novartis. In those roles he oversaw the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix.
Working at the National Cancer Institute from 1990 to 1997, Dr. Parkinson served as Chief of the Investigational Drug Branch and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP). He is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, a past member of the FDA Science Board, and is a recipient of the FDA’s Cody Medal. He is a past editor of the Journal of Immunotherapy and past president of the Society of Biological Therapy.
Dr. Parkinson has served on the National Cancer Policy Forum of the Institute of Medicine and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. A past Board Director of the Ontario Institute for Cancer Research, he currently serves as a Board Director for the Multiple Myeloma Research Foundation. He served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committe for 15 years and is a previous elected Board Director of AACR. Dr. Parkinson was a Director of Facet Biotech, Inc., until the acquisition by Abbott Pharmaceuticals, and was a Director of Ambit Biosciences until the acquisition by Daiichi Sankyo. He was also previously a Director at Threshold Pharmaceuticals and Cerulean Pharmaceuticals. He currently serves as Director on the Boards of Tocagen Inc (TOCA), 3SBio Inc (1530.HK), CTI Biopharma, Inc (CTIC), and is a Co-Founder and Director of Refuge Biotech, Inc.
He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.